Liselot Valkenburg‐van Iersel
A5011221289- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Gallbladder and Bile Duct Disorders
- Gut microbiota and health
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Neuroendocrine Tumor Research Advances
- Cancer survivorship and care
- Colorectal and Anal Carcinomas
- Nutrition and Health in Aging
- Oral health in cancer treatment
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Mycobacterium research and diagnosis
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Melanoma and MAPK Pathways
- Frailty in Older Adults
- PARP inhibition in cancer therapy
- Pancreatitis Pathology and Treatment
Maastricht University
2020-2025
Maastricht University Medical Centre
2020-2024
University Medical Center
2021-2024
Dutch Colorectal Cancer Group
2024
Leiden University Medical Center
2011
DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of DPYD variant alleles. However, the impact on treatment outcome these patients is largely unknown. Therefore, progression-free survival (PFS) and overall (OS) were compared between treated with a reduced dose wild-type controls receiving full retrospective matched-pair analysis.Data from prospective multicenter study (ClinicalTrials.gov identifier: NCT02324452) which received 25% (c.1236G>A c.2846A>T) or 50% (DPYD*2A...
Perihilar cholangiocarcinoma (pCCA) is a rare tumour that requires complex multidisciplinary management. All known data are almost exclusively derived from expert centres. This study aimed to analyse the outcomes of patients with pCCA in nationwide cohort.Data on all diagnosed Netherlands between 2010 and 2018 were obtained Cancer Registry. Data included type hospital diagnosis received treatment. Outcomes treatment overall survival.A total 2031 median survival for cohort was 5.2 (95% CI...
Abstract Background Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection who might benefit form adjuvant chemotherapy (ACT). Presence circulating tumor DNA (ctDNA) is indicative MRD and has high predictive value recurrent disease. The MEDOCC-CrEATE trial investigates how many CC detectable ctDNA will accept ACT whether reduces the risk recurrence in these patients....
BackgroundThe aim of this nationwide cohort study was to examine the course symptoms and trajectories health-related quality life (HR-QoL) psychological distress during follow-up identify vulnerable patients.MethodsPatients with pathological stage I–III colorectal cancer (CRC) between 2013 2018 were included. Baseline characteristics collected from Netherlands Cancer Registry, patients completed European Organisation for Research Treatment QLQ-C30/CR29, Hospital Anxiety Depression Scale low...
BackgroundIn 2–5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in one-third these patients, it not approved for this indication Europe. In the Drug Rediscovery Protocol (DRUP), are treated off-label drugs based on their molecular profile. Here, we present results cohort 'trastuzumab/pertuzumab treatment-refractory RAS/BRAF-wild-type HER2amplified...
Periampullary adenocarcinoma consists of pancreatic (PDAC), distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal (DA). The aim this study was to assess treatment modalities overall survival by tumor origin.Patients diagnosed with non-metastatic periampullary in 2012-2018 were identified from the Netherlands Cancer Registry. OS studied Kaplan-Meier analysis multivariable Cox regression analyses, stratified origin.Among 8758 patients included, 68% had PDAC, 13% DC, 12% AC, 7%...
Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked Netherlands Registry, serves as an infrastructure for scientific collecting additional patient-reported outcomes (PRO) biospecimens. Here we report on cohort developments investigate what extent PLCRC reflects "real-world". Clinical demographic characteristics of participants were compared with...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers known to humans. However, not all patients fare equally poor survival, and a minority even survives advanced disease for months or years. Thus, there clinical need search corresponding prognostic biomarkers which forecast survival on an individual basis. To dig more information identify potential from PDAC pathological slides, we trained deep learning (DL) model based U-net-shaped backbone. This DL can...
ABSTRACT Dose-limiting toxicities pose a major barrier to cancer treatment. While preclinical studies show that the gut microbiota influences and is influenced by anticancer drugs, data from patients paired with careful side effect monitoring remains limited. Here, we investigate capecitabine (CAP)-microbiome interactions through longitudinal metagenomic sequencing of stool 56 advanced colorectal patients. CAP significantly altered microbiome, enriching for menaquinol (vitamin K2)...
Gut bacteria-derived short-chain fatty acids (SCFA) and branched-chain (BCFA) are considered to have beneficial metabolic, anti-inflammatory as well anti-carcinogenic effects. Previous preclinical studies indicated bidirectional interactions between gut bacteria the chemotherapeutic capecitabine or its metabolite 5-FU. This study investigated effect of three cycles on fecal SCFA BCFA levels their associations with tumor response, nutritional status, physical performance, chemotherapy-induced...
BackgroundThe COVID-19 pandemic has put substantial strain on the healthcare system of which effects are only partly elucidated. This study aimed to investigate impact pancreatic cancer care.MethodsAll patients diagnosed with between 2017 and 2020 were selected from Netherlands Cancer Registry. Patients and/or treated in compared 2017–2019. Monthly incidence was calculated. Patient, tumor treatment characteristics analyzed using Chi-squared tests. Survival data Kaplan–Meier Log-rank...
BackgroundMost data on the treatment and outcomes of intrahepatic cholangiocarcinoma (iCCA) derives from expert centers. This study aimed to investigate all patients diagnosed with iCCA in a nationwide cohort.MethodsData between 2010 2018 were obtained Netherlands Cancer Registry.ResultsIn total, 1747 included. Resection was performed 292 (17%), 548 (31%) underwent palliative systemic treatment, 867 (50%) best supportive care (BSC). The OS median 1-, 3-year after resection: 37.5 months...
Bowel dysfunction after rectal cancer surgery is common, with some experiencing low anterior resection syndrome (LARS) common surgery. This study examined if transanal total mesorectal excision (TaTME) has a similar risk of LARS and altered quality life (QoL) as patients who undergo (LAR).Patients underwent TaTME or traditionally approached in prospective colorectal cohort (2014-2019) were propensity score matched 1 : ratio. QoL scores assessed before primary endpoint major at 12 months...
Previous pre-clinical research has indicated that the intestinal microbiota can potentiate anti-tumour efficacy of capecitabine and treatment impacts composition diversity. Using a longitudinal design, this study explores associations between response in patients with metastatic colorectal cancer (mCRC) during treatment.Patients mCRC treated were prospectively enrolled multicentre cohort study. Patients collected faecal sample completed questionnaire before, during, after three cycles...
The aim of this retrospective study was to determine the patterns recurrence and overall survival (OS) in patients achieving clinical complete response after treatment with definitive chemoradiation (CRT) for proximal esophageal cancer.Patients cancer treated CRT between 2004 2014 11 centers Netherlands were included. OS progression-free (PFS) calculated using Kaplan-Meier method. Cumulative incidence first (locoregional or distant) locoregional (LRR) assessed competing risk analyses.In 197...
The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic ductal adenocarcinoma (PDAC) was shown by the ESPAC-4 trial. Real-world data on effectiveness plus (GEMCAP), patients ineligible for mFOLFIRINOX, are lacking. Our study assessed whether GEMCAP is superior GEM a nationwide cohort. Patients treated with or after resection PDAC without preoperative treatment were identified from Netherlands Cancer Registry (2015-2019). primary outcome overall survival (OS),...
Regular physical activity (PA) is associated with improved overall survival (OS) in stage I-III colorectal cancer (CRC) patients. This association less defined patients metastatic CRC (mCRC). We therefore conducted a study mCRC participating the Prospective Dutch Colorectal Cancer cohort. PA was assessed validated SQUASH questionnaire, filled-in within maximum of 60 days after diagnosis mCRC. quantified by calculating Metabolic Equivalent Task (MET) hours per week. American College Sports...
The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo pretreated metastatic colorectal cancer (mCRC) patients. Unfortunately, quality of life (QoL) was not assessed. We evaluated QoL and patients treated with FTD/TPI daily practice.QUALITAS is substudy the Prospective Dutch CRC cohort (PLCRC). From 150 mCRC FTD/TPI, (EORTC QLQ-C30 QLQ-CR29) assessed monthly from study entry, linked to clinical data Netherlands Cancer...